Allergy Therapeutics plc (LON:AGY – Get Free Report)’s share price traded down 7.2% during mid-day trading on Thursday . The company traded as low as GBX 4.50 ($0.06) and last traded at GBX 4.64 ($0.06). 604,014 shares were traded during trading, a decline of 19% from the average session volume of 741,667 shares. The stock had previously closed at GBX 5 ($0.07).
Allergy Therapeutics Price Performance
The business’s 50 day simple moving average is GBX 4.49 and its 200 day simple moving average is GBX 4.25. The company has a current ratio of 1.40, a quick ratio of 1.48 and a debt-to-equity ratio of 37.22. The firm has a market capitalization of £238.50 million, a PE ratio of -77.33, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Featured Stories
- Five stocks we like better than Allergy Therapeutics
- The Basics of Support and Resistance
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What is a Bond Market Holiday? How to Invest and Trade
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Are Some of the Best Large-Cap Stocks to Buy?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
